Ipsen: worldwide licensing agreement with Foreseen
Identified using Foreseen's proprietary proteomics platforms, this antibody-drug conjugate has demonstrated robust preclinical efficacy in multiple tumor types and a favorable preclinical safety profile, according to Ipsen.
Foreseen will receive up to $1.03 billion in upfront and milestone payments. It may also receive tiered royalties on worldwide sales.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction